IL2 and neoplasm: Jensen et al. [67] reported that IL-2-based therapy leads to the accumulation of FOXP3-positive immune cells in the tumor microenvironment in metastatic renal cell carcinoma and that high numbers of on-treatment FOXP3-positive cells were correlated with poor prognosis.